Reply to: Comment on “Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review”

To the Editor: We would like to thank Dr Asahina and Dr Nakagawa1 for taking interest in our publication entitled "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review."2 In our initial assessment of their clinical trial report (M04-688; NCT00338754), we were not able to infer any statistical difference in efficacy between the 2 dosing regimens, 40 mg every other week (EOW) and 80-mg loading dose followed by 40 mg EOW.3 However, we are pleased to learn that a statistical analysis directly comparing the efficacy of the 2 groups was completed and established a more rapid improvement of psoriatic plaques with the regimen including a loading dose.